Ocugen to Participate in Upcoming May Scientific and Investor Conferences
Rhea-AI Summary
Ocugen (NASDAQ: OCGN) will present its modifier gene therapy platform at scientific and investor events in May 2026.
Presentations include the Retina World Congress Inherited and Rare Retinal Diseases Session on May 14, 2026, and the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026, with a webcast and 30-day replay.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 05 | Earnings update | Positive | -19.5% | Q1 2026 results plus positive OCU400/OCU410 data and runway extension. |
| May 05 | Debt financing | Negative | -19.5% | Pricing of $115M 6.75% convertible senior notes in private offering. |
| May 04 | Financing announce | Negative | -19.5% | Announcement of proposed $115M convertible senior notes private offering. |
| Apr 29 | Earnings call plan | Neutral | +1.2% | Scheduling Q1 2026 earnings call and webcast details for May 5. |
| Apr 23 | Conference outreach | Positive | -0.6% | April investor conferences with focus on modifier gene therapy platform and OCU400 BLA plans. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows sharp negative reactions to financing/earnings updates, while conference and routine communication items have seen modest or mixed moves.
Over the last few weeks, Ocugen has focused on financing and pipeline visibility. On Apr 23, it highlighted investor conferences and a planned OCU400 BLA, with shares nearly flat. Late April and early May brought an earnings update and a series of convertible note announcements, each followed by a -19.46% move, indicating sensitivity to dilution and funding headlines. Earlier, a May 5 earnings call announcement on Apr 29 saw a slight positive reaction. Today’s conference participation fits into this ongoing push to showcase its modifier gene therapy platform to scientific and investor audiences.
Key Terms
gene therapies medical
modifier gene therapy medical
inherited and rare retinal diseases medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific and investor conferences in May 2026.
Retina World Congress
Inherited and Rare Retinal Diseases Session
Moderators: Kourous A. Rezaei, MD and Rishi P. Singh, MD, FASRS
Location: Grand Ballroom
Date: Thursday, May 14, 2026
Time: 10:31 am – 11:10 a.m. EDT
Stifel 2026 Virtual Ophthalmology Forum
Location: Virtual
Date: Tuesday, May 26, 2026
Time: 10:30 am – 10:55 a.m. EDT
A webcast of the Stifel presentation will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit Investors | Ocugen, Inc.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Investor Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com
